ANI Pharmaceuticals - Public Comps and Valuation Multiples

ANI Pharmaceuticals Overview

About ANI Pharmaceuticals

ANI Pharmaceuticals Inc develops, manufactures, and markets generic prescription pharmaceuticals. It manufactures liquid, powder, and oral solid-dose products. Its areas of product development include narcotics, oncolytics, hormones and steroids, and complex formulations involving extended-release and combination products. Some of its generic products include Erythromycin ethyl succinate, Esterified Estrogen with Methyltestosterone (EEMT), Etodolac Fenofibrate, Fluvoxamine, Hydrocortisone Enema and Vancomycin. The company operates in two segments which include Rare Diseases and Brands, Generics, and Others. Its geographical segments are the United States and Canada, of which the majority of its revenue comes from the United States.

Founded

2001

HQ

Employees

897

Website

anipharmaceuticals.com

Sectors

Biopharmaceuticals
Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $800M

LTM EBITDA $209M

EV

$2.5B

Valuation Multiples

Multiples.vc

Valuation Multiples for 15K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

ANI Pharmaceuticals Financials

As of September 2025, ANI Pharmaceuticals reported last 12-month revenue of $800M and EBITDA of $209M.

In the same period, ANI Pharmaceuticals generated $505M in LTM gross profit and $143M in net income.

See ANI Pharmaceuticals valuation multiples based on analyst estimates

ANI Pharmaceuticals P&L

In the most recent fiscal year, ANI Pharmaceuticals reported revenue of $614M and EBITDA of $63.1M.

ANI Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX

See ANI Pharmaceuticals valuation multiples based on analyst estimates

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue	$800M	XXX	$614M	XXX	XXX	XXX
Gross Profit	$505M	XXX	$364M	XXX	XXX	XXX
Gross Margin	63%	XXX	59%	XXX	XXX	XXX
EBITDA	$209M	XXX	$63.1M	XXX	XXX	XXX
EBITDA Margin	26%	XXX	10%	XXX	XXX	XXX
EBIT	$208M	XXX	$2.2M	XXX	XXX	XXX
EBIT Margin	26%	XXX	0%	XXX	XXX	XXX
Net Profit	$143M	XXX	-$18.5M	XXX	XXX	XXX
Net Margin	18%	XXX	-3%	XXX	XXX	XXX
Net Debt	XXX	XXX	$479M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

.seo-only-financials-wrapper { position: static; left: auto; width: auto; height: auto; overflow: visible; }

Financial performance metrics for ANI Pharmaceuticals including revenue, profitability, and margin analysis across different time periods. The company reported last twelve months revenue of $800M. EBITDA for the last twelve months was $209M. In the most recent fiscal year, ANI Pharmaceuticals achieved $614M in revenue and $63.1M in EBITDA.
Financial Metric	Last Twelve Months (LTM)	Next Twelve Months (NTM)	Most Recent Fiscal Year	Current Fiscal Year (2025)	Next Fiscal Year (2026)	Two Years Forward (2027)
Total Revenue	$800M	Analyst estimates available to subscribers	$614M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit	$505M	Analyst estimates available to subscribers	$364M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Gross Profit Margin	63.2% gross margin	Analyst estimates available to subscribers	59.3% gross profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA (Earnings Before Interest, Taxes, Depreciation, Amortization)	$209M	Analyst estimates available to subscribers	$63.1M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBITDA Margin	26.2% EBITDA margin	Analyst estimates available to subscribers	10.3% EBITDA margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT (Earnings Before Interest and Taxes)	$208M	Analyst estimates available to subscribers	$2.2M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
EBIT Margin	26.0% EBIT margin	Analyst estimates available to subscribers	0.4% EBIT margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Income (Net Profit)	$143M	Analyst estimates available to subscribers	-$18.5M	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Profit Margin	17.9% net profit margin	Analyst estimates available to subscribers	-3.0% net profit margin	Analyst estimates available to subscribers	Analyst estimates available to subscribers	Analyst estimates available to subscribers
Net Debt Position	Detailed debt information available to subscribers	Detailed debt information available to subscribers	$479M	Detailed debt information available to subscribers	Detailed debt information available to subscribers	Detailed debt information available to subscribers

Financial Performance Summary for ANI Pharmaceuticals

This financial data table provides comprehensive performance metrics for ANI Pharmaceuticals, a company based in United States of America. The metrics include revenue, profitability measures, and operational efficiency indicators across multiple time periods.

Recent Performance Highlights

ANI Pharmaceuticals generated $800M in revenue over the last twelve months.
The company achieved $209M in EBITDA over the last twelve months.
Gross profit for the last twelve months was $505M.
Net income over the last twelve months reached $143M.

Fiscal Year Performance

In the most recent fiscal year, ANI Pharmaceuticals reported $614M in total revenue.
Fiscal year EBITDA was $63.1M.
The company maintained a gross profit margin of 59.3% in the most recent fiscal year.
EBITDA margin for the fiscal year was 10.3%.
Net profit margin reached -3.0% in the most recent fiscal year.

This financial data is sourced from Morningstar, Inc. and represents the most recent available information for ANI Pharmaceuticals. Forward-looking estimates and detailed financial projections are available through our premium subscription service.

ANI Pharmaceuticals Stock Performance

ANI Pharmaceuticals has current market cap of $2.1B, and EV of $2.5B.

Market Cap Evolution

ANI Pharmaceuticals Stock Data

As of October 17, 2025, ANI Pharmaceuticals's stock price is $95.

See ANI Pharmaceuticals trading valuation data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$2.5B	$2.1B	XXX	XXX	XXX	XXX	$6.89

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Start Free Trial

ANI Pharmaceuticals Valuation Multiples

ANI Pharmaceuticals's trades at 4.1x EV/Revenue multiple, and 40.2x EV/EBITDA.

See valuation multiples for ANI Pharmaceuticals and 15K+ public comps

ANI Pharmaceuticals Financial Valuation Multiples

As of October 17, 2025, ANI Pharmaceuticals has market cap of $2.1B and EV of $2.5B.

Equity research analysts estimate ANI Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

ANI Pharmaceuticals has a P/E ratio of 14.8x.

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Market cap (current)	$2.1B	XXX	$2.1B	XXX	XXX	XXX
EV (current)	$2.5B	XXX	$2.5B	XXX	XXX	XXX
EV/Revenue	3.2x	XXX	4.1x	XXX	XXX	XXX
EV/EBITDA	12.1x	XXX	40.2x	XXX	XXX	XXX
EV/EBIT	12.2x	XXX	1143.3x	XXX	XXX	XXX
EV/Gross Profit	5.0x	XXX	n/a	XXX	XXX	XXX
P/E	14.8x	XXX	-114.1x	XXX	XXX	XXX
EV/FCF	18.3x	XXX	53.9x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get ANI Pharmaceuticals Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Start Free Trial

ANI Pharmaceuticals Margins & Growth Rates

ANI Pharmaceuticals's last 12 month revenue growth is 14%

ANI Pharmaceuticals's revenue per employee in the last FY averaged $0.7M, while opex per employee averaged $0.4M for the same period.

ANI Pharmaceuticals's rule of 40 is 35% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

ANI Pharmaceuticals's rule of X is 60% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

See operational valuation multiples for ANI Pharmaceuticals and other 15K+ public comps

ANI Pharmaceuticals Operational Valuation Multiples

	LTM	NTM	Last FY	FY 2025	FY 2026	FY 2027
Revenue Growth	14%	XXX	23%	XXX	XXX	XXX
EBITDA Margin	26%	XXX	10%	XXX	XXX	XXX
EBITDA Growth	16%	XXX	44%	XXX	XXX	XXX
Rule of 40	35%	XXX	24%	XXX	XXX	XXX
Bessemer Rule of X	XXX	XXX	60%	XXX	XXX	XXX
Revenue per Employee	XXX	XXX	$0.7M	XXX	XXX	XXX
Opex per Employee	XXX	XXX	$0.4M	XXX	XXX	XXX
S&M Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
G&A Expenses to Revenue	XXX	XXX	n/a	XXX	XXX	XXX
R&D Expenses to Revenue	XXX	XXX	7%	XXX	XXX	XXX
Opex to Revenue	XXX	XXX	59%	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry

Start Free Trial